The mRNA vaccine program once poised to counter threats like avian flu is being dismantled under Health Secretary Robert F. Kennedy Jr., risking slower responses to emerging infectious diseases.
Devi Sridhar writes for The Guardian.
In short:
- Kennedy has cancelled $500 million in mRNA vaccine research, including a late-stage H5N1 avian flu project at Moderna.
- The avian flu virus has spread among wild birds, poultry, and U.S. dairy cattle, and is now one mutation away from easier human transmission.
- Cuts are closing research programs, stalling PhD and postdoctoral positions, and pushing young scientists out of public health fields.
Key quote:
“A self-inflicted wound to a vital organ.”
— Rebecca Katz, global health security expert and former U.S. State Department adviser
Why this matters:
Emerging infectious diseases such as H5N1 avian flu can leap from animals to humans with little warning, creating conditions for global outbreaks. The mRNA vaccine platform, developed and refined during the Covid-19 pandemic, offers a rare advantage in producing targeted vaccines in weeks rather than months. Halting U.S. investment in this technology reduces the country’s ability to respond rapidly to new threats and leaves more people vulnerable in the early stages of an outbreak — precisely when containment is most critical. Without sustained funding, the scientific workforce and manufacturing infrastructure needed for this rapid response will erode, increasing reliance on slow or unreliable foreign supply chains and risking a repeat of the deadly delays seen in past pandemics.
Learn more: CDC faces leadership vacuum as RFK Jr wields direct authority over vaccine decisions
